Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Employees - 70000,
CEO - Mr. Robert M. Davis J.D.,
Sector - Healthcare,
Country - US,
Market Cap - 244.37B
Altman ZScore(max is 10): 3.83, Piotroski Score(max is 10): 7, Working Capital: $10775000000, Total Assets: $117532000000, Retained Earnings: $61384000000, EBIT: 14973000000, Total Liabilities: $72972000000, Revenue: $63218000000
AryaFin Target Price - $135.45 - Current Price $98.05 - Analyst Target Price $128.00
Ticker | MRK |
Index | DJIA, S&P 500 |
Curent Price | 98.05 |
Change | -1.48% |
Market Cap | 244.37B |
Average Volume | 11.33M |
Income | 12.15B |
Sales | 62.89B |
Book Value/Share | 17.58 |
Cash/Share | 5.87 |
Dividend Est | 3.10 (3.16%) |
Dividend TTM | 3.12 (3.18%) |
Dividend Ex-Date | Dec 16, 2024 |
Employees | 72000 |
Moving Avg 20days | -2.97% |
Moving Avg 50days | -4.22% |
Moving Avg 200days | -16.85% |
Shares Outstanding | 2.53B |
Earnings Date | Oct 31 BMO |
Inst. Ownership | 78.92% |
Price/Earnings | 20.54 |
Forwad P/E | 10.39 |
PE Growth | 0.73 |
Price/Sales | 3.89 |
Price/Book | 5.58 |
Price/Cash | 16.70 |
Price/FCF | 16.47 |
Quick Ratio | 1.15 |
Current Ratio | 1.36 |
Debt/Equity | 0.86 |
Return on Assets | 10.83% |
Return on Equity | 28.33% |
Return on Investment | 15.28% |
Gross Margin | 73.03% |
Ops Margin | 23.00% |
Profit Margin | 19.32% |
RSI | 40.50 |
BETA(β) | 0.41 |
From 52week Low | 3.78% |
From 52week High | -27.17% |
EPS | 4.77 |
EPS next Year | 9.44 |
EPS next Qtr | 1.81 |
EPS this Year | 412.48% |
EPS next 5 Year | 28.00% |
EPS past 5 Year | -42.70% |
Sales past 5 Year | 7.72% |
EPS Y/Y | 163.70% |
Sales Y/Y | 8.17% |
EPS Q/Q | -33.34% |
Sales Q/Q | 4.42% |
Sales Surprise | 1.11% |
EPS Surprise | 5.80% |
ATR(14) | 2.20 |
Perf Week | -3.87% |
Perf Month | 0.63% |
Perf Quarter | -15.20% |
Perf Year | -6.94% |
Perf YTD | -10.06% |
Target Price | 128.00 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer